Tamar B Nobel1, Jennifer Livschitz2, Xin Xin Xing3, Arianna Barbetta2, Meier Hsu4, Kay See Tan4, Smita Sihag2, David R Jones2, Daniela Molena5. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Surgery, Mount Sinai Hospital, New York, New York. 2. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Hunter College, City University of New York, New York. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: molenad@mskcc.org.
Abstract
BACKGROUND: There are limited data regarding optimal surveillance after curative resection for esophageal cancer. Once disease recurrence is diagnosed, the prognosis is poor. The purpose of this article was to characterize disease recurrence in patients with early esophageal adenocarcinoma. METHODS: Two hundred sixty patients were identified from a prospective institutional database with pathologic T1 and T2 node-negative disease therapy treated with curative esophagectomy alone for esophageal adenocarcinoma between 1995 and 2017. Competing risk analysis was used to analyze factors associated with recurrence. RESULTS: The 5-year cumulative incidence of recurrence was 12%. Predictive factors for increased risk of recurrence included increasing tumor size, poor differentiation, and pathologic T2 disease (P < .05), whereas presence of Barrett's esophagus on pathology was protective. Recurrence within 2 years was 2.5%, 6.1%, and 12% for T1a, T1b, and T2 disease, respectively. At 5 years cumulative incidence of recurrence was 8.2%, 11.5% and 22.2%, respectively. Median overall survival after recurrence was 1.04 years (95% confidence interval, 0.7-2.4). There were 14 subclinical and 13 symptomatic recurrences; patients with symptomatic recurrence had a significantly shorter overall survival after recurrence occurred (0.31 vs 0.71 years, P = .018). CONCLUSIONS: Among early node-negative patients with esophageal cancer undergoing curative resection, 5-year recurrence was 12%. Survival after recurrence was poor, and only a few patients had isolated locoregional recurrence at time of diagnosis, suggesting that scheduled surveillance may have an important role.
BACKGROUND: There are limited data regarding optimal surveillance after curative resection for esophageal cancer. Once disease recurrence is diagnosed, the prognosis is poor. The purpose of this article was to characterize disease recurrence in patients with early esophageal adenocarcinoma. METHODS: Two hundred sixty patients were identified from a prospective institutional database with pathologic T1 and T2 node-negative disease therapy treated with curative esophagectomy alone for esophageal adenocarcinoma between 1995 and 2017. Competing risk analysis was used to analyze factors associated with recurrence. RESULTS: The 5-year cumulative incidence of recurrence was 12%. Predictive factors for increased risk of recurrence included increasing tumor size, poor differentiation, and pathologic T2 disease (P < .05), whereas presence of Barrett's esophagus on pathology was protective. Recurrence within 2 years was 2.5%, 6.1%, and 12% for T1a, T1b, and T2 disease, respectively. At 5 years cumulative incidence of recurrence was 8.2%, 11.5% and 22.2%, respectively. Median overall survival after recurrence was 1.04 years (95% confidence interval, 0.7-2.4). There were 14 subclinical and 13 symptomatic recurrences; patients with symptomatic recurrence had a significantly shorter overall survival after recurrence occurred (0.31 vs 0.71 years, P = .018). CONCLUSIONS: Among early node-negative patients with esophageal cancer undergoing curative resection, 5-year recurrence was 12%. Survival after recurrence was poor, and only a few patients had isolated locoregional recurrence at time of diagnosis, suggesting that scheduled surveillance may have an important role.
Authors: Emmanuele Abate; Steven R DeMeester; Joerg Zehetner; Arzu Oezcelik; Shahin Ayazi; Jesse Costales; Farzaneh Banki; John C Lipham; Jeffrey A Hagen; Tom R DeMeester Journal: J Am Coll Surg Date: 2010-04 Impact factor: 6.113
Authors: Julia R Berian; Amanda Cuddy; Amanda B Francescatti; Linda O'Dwyer; Y Nancy You; Robert J Volk; George J Chang Journal: J Cancer Surviv Date: 2017-06-22 Impact factor: 4.442
Authors: Lawrence Lee; Ulrich Ronellenfitsch; Wayne L Hofstetter; Gail Darling; Timo Gaiser; Christiane Lippert; Sebastien Gilbert; Andrew J Seely; David S Mulder; Lorenzo E Ferri Journal: J Am Coll Surg Date: 2013-05-06 Impact factor: 6.113
Authors: Galal Ghaly; Sebron Harrison; Mohamed K Kamel; Mohamed Rahouma; Abu Nasar; Jeffrey L Port; Brendon M Stiles; Nasser K Altorki Journal: Ann Thorac Surg Date: 2017-12-21 Impact factor: 4.330
Authors: L Depypere; T Lerut; J Moons; W Coosemans; G Decker; H Van Veer; P De Leyn; P Nafteux Journal: Dis Esophagus Date: 2017-01-01 Impact factor: 3.429
Authors: Paul C Lee; Farooq M Mirza; Jeffrey L Port; Brendon M Stiles; Subroto Paul; Paul Christos; Nasser K Altorki Journal: J Thorac Cardiovasc Surg Date: 2011-03-12 Impact factor: 5.209
Authors: Tamar B Nobel; Arianna Barbetta; Meier Hsu; Kay See Tan; Smita Sihag; Manjit S Bains; David R Jones; Daniela Molena Journal: J Am Coll Surg Date: 2019-05-17 Impact factor: 6.113
Authors: Smita Sihag; Sergio De La Torre; Meier Hsu; Tamar Nobel; Kay See Tan; Hans Gerdes; Pari Shah; Manjit Bains; David R Jones; Daniela Molena Journal: J Thorac Cardiovasc Surg Date: 2020-11-24 Impact factor: 6.439
Authors: Joerg Lindenmann; Melanie Fediuk; Nicole Fink-Neuboeck; Christian Porubsky; Martin Pichler; Luka Brcic; Udo Anegg; Marija Balic; Nadia Dandachi; Alfred Maier; Maria Smolle; Josef Smolle; Freyja Maria Smolle-Juettner Journal: Cancers (Basel) Date: 2020-07-27 Impact factor: 6.639
Authors: Noel E Donlon; Maria Davern; Andrew D Sheppard; Fiona O'Connell; Margaret R Dunne; Conall Hayes; Eimear Mylod; Sinead Ramjit; Hugo Temperley; Michael Mac Lean; Gillian Cotter; Anshul Bhardwaj; Christine Butler; Melissa J Conroy; Jacintha O'Sullivan; Narayanasamy Ravi; Claire L Donohoe; John V Reynolds; Joanne Lysaght Journal: Front Immunol Date: 2022-01-27 Impact factor: 7.561
Authors: A Justin Rucker; Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; David H Harpole; Thomas A D'Amico; Betty C Tong Journal: Ann Surg Date: 2022-02-01 Impact factor: 13.787